Global Diagnostic Radiopharmaceuticals Market Overview And Scope:
Global Diagnostic Radiopharmaceuticals Market Size was estimated at USD 4392.69 million in 2022 and is projected to reach USD 6580.8 million by 2028, exhibiting a CAGR of 6.97% during the forecast period.
The Global Diagnostic Radiopharmaceuticals Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Diagnostic Radiopharmaceuticals utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: Cardinal Health, GE Healthcare, Curium Pharma, Jubilant Pharma, Bracco Imaging, Advanced Accelerator Applications, SIEMENS, China Isotope and Radiation, Dongcheng Pharmaceutical Group, Lantheus, Eli Lilly
Global Diagnostic Radiopharmaceuticals Market Segmentation
By Type, Diagnostic Radiopharmaceuticals market has been segmented into:Technetium 99
Fluorine 18
Other
By Application, Diagnostic Radiopharmaceuticals market has been segmented into:
Oncology
Cardiology
Other
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Diagnostic Radiopharmaceuticals market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Diagnostic Radiopharmaceuticals market.
Top Key Players Covered in Diagnostic Radiopharmaceuticals market are:
Cardinal Health
GE Healthcare
Curium Pharma
Jubilant Pharma
Bracco Imaging
Advanced Accelerator Applications
SIEMENS
China Isotope and Radiation
Dongcheng Pharmaceutical Group
Lantheus
Eli Lilly
Objective to buy this Report:
1. Diagnostic Radiopharmaceuticals analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Diagnostic Radiopharmaceuticals market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Diagnostic Radiopharmaceuticals Market by Type
5.1 Diagnostic Radiopharmaceuticals Market Overview Snapshot and Growth Engine
5.2 Diagnostic Radiopharmaceuticals Market Overview
5.3 Technetium 99
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Technetium 99: Geographic Segmentation
5.4 Fluorine 18
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Fluorine 18: Geographic Segmentation
5.5 Other
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Other: Geographic Segmentation
Chapter 6: Diagnostic Radiopharmaceuticals Market by Application
6.1 Diagnostic Radiopharmaceuticals Market Overview Snapshot and Growth Engine
6.2 Diagnostic Radiopharmaceuticals Market Overview
6.3 Oncology
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Oncology: Geographic Segmentation
6.4 Cardiology
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Cardiology: Geographic Segmentation
6.5 Other
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Diagnostic Radiopharmaceuticals Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Diagnostic Radiopharmaceuticals Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Diagnostic Radiopharmaceuticals Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 CARDINAL HEALTH
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 GE HEALTHCARE
7.4 CURIUM PHARMA
7.5 JUBILANT PHARMA
7.6 BRACCO IMAGING
7.7 ADVANCED ACCELERATOR APPLICATIONS
7.8 SIEMENS
7.9 CHINA ISOTOPE AND RADIATION
7.10 DONGCHENG PHARMACEUTICAL GROUP
7.11 LANTHEUS
7.12 ELI LILLY
Chapter 8: Global Diagnostic Radiopharmaceuticals Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Technetium 99
8.2.2 Fluorine 18
8.2.3 Other
8.3 Historic and Forecasted Market Size By Application
8.3.1 Oncology
8.3.2 Cardiology
8.3.3 Other
Chapter 9: North America Diagnostic Radiopharmaceuticals Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Technetium 99
9.4.2 Fluorine 18
9.4.3 Other
9.5 Historic and Forecasted Market Size By Application
9.5.1 Oncology
9.5.2 Cardiology
9.5.3 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Diagnostic Radiopharmaceuticals Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Technetium 99
10.4.2 Fluorine 18
10.4.3 Other
10.5 Historic and Forecasted Market Size By Application
10.5.1 Oncology
10.5.2 Cardiology
10.5.3 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Diagnostic Radiopharmaceuticals Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Technetium 99
11.4.2 Fluorine 18
11.4.3 Other
11.5 Historic and Forecasted Market Size By Application
11.5.1 Oncology
11.5.2 Cardiology
11.5.3 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Diagnostic Radiopharmaceuticals Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Technetium 99
12.4.2 Fluorine 18
12.4.3 Other
12.5 Historic and Forecasted Market Size By Application
12.5.1 Oncology
12.5.2 Cardiology
12.5.3 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Diagnostic Radiopharmaceuticals Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Technetium 99
13.4.2 Fluorine 18
13.4.3 Other
13.5 Historic and Forecasted Market Size By Application
13.5.1 Oncology
13.5.2 Cardiology
13.5.3 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Diagnostic Radiopharmaceuticals Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Technetium 99
14.4.2 Fluorine 18
14.4.3 Other
14.5 Historic and Forecasted Market Size By Application
14.5.1 Oncology
14.5.2 Cardiology
14.5.3 Other
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Diagnostic Radiopharmaceuticals Scope:
|
Report Data
|
Diagnostic Radiopharmaceuticals Market
|
|
Diagnostic Radiopharmaceuticals Market Size in 2025
|
USD XX million
|
|
Diagnostic Radiopharmaceuticals CAGR 2025 - 2032
|
XX%
|
|
Diagnostic Radiopharmaceuticals Base Year
|
2024
|
|
Diagnostic Radiopharmaceuticals Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Cardinal Health, GE Healthcare, Curium Pharma, Jubilant Pharma, Bracco Imaging, Advanced Accelerator Applications, SIEMENS, China Isotope and Radiation, Dongcheng Pharmaceutical Group, Lantheus, Eli Lilly.
|
|
Key Segments
|
By Type
Technetium 99
Fluorine 18
Other
By Applications
Oncology
Cardiology
Other
|
